Cellectar Biosciences, Inc. (CLRB)

Market Cap	9.70M
Revenue (ttm)	n/a
Net Income (ttm)	-50.11M
Shares Out	41.27M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,162,132
Open	0.240
Previous Close	0.238
Day's Range	0.230 - 0.250
52-Week Range	0.220 - 4.450
Beta	0.87
Analysts	Buy
Price Target	28.00 (+11,814.89%)
Earnings Date	Nov 18, 2024

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: CLRB
• Website: https://www.cellectar.com

Analyst Forecast

According to 2 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is $28.0, which is an increase of 11,814.89% from the latest price.

Price Target

$28.0

(11,814.89% upside)

Analyst Consensus: Buy